ENTRY hsa05200 Pathway NAME Pathways in cancer - Homo sapiens (human) CLASS Human Diseases; Cancer: overview PATHWAY_MAP hsa05200 Pathways in cancer DRUG D00094 Tretinoin (JAN/USP/INN) D00327 Fluoxymesterone (JAN/USP/INN) D00408 Methyltestosterone (JP18/USP/INN) D00554 Ethinyl estradiol (USP) D00586 Flutamide (JP18/USP/INN) D00745 Interferon alfa-2a (USAN/INN) D00747 Interferon gamma-1b (USAN/INN) D00748 Aldesleukin (USAN/INN) D00753 Sirolimus (JAN/USAN/INN) D00958 Testosterone enanthate (JP18/USP) D00961 Bicalutamide (JP18/USP/INN) D00965 Nilutamide (USAN/INN) D00966 Tamoxifen citrate (JP18/USP) D00967 Toremifene citrate (JAN/USAN) D01161 Fulvestrant (JAN/USP/INN) D01441 Imatinib mesylate (USAN) D01534 Dromostanolone propionate (USAN) D01977 Gefitinib (JP18/USAN/INN) D02106 Arsenic trioxide (JP18/USAN) D02714 Everolimus (JAN/USAN/INN) D02745 Interferon alfa-2b (USAN) D02748 Peginterferon alfa-2b (USAN/INN) D02815 Alitretinoin (USAN) D02970 Aprinocarsen sodium (USAN) D03061 Batimastat (USAN/INN) D03106 Bexarotene (JAN/USAN/INN) D03218 Axitinib (JAN/USAN) D03235 Filgrastim (USP/INN) D03247 Lenograstim (USAN/INN) D03252 Bosutinib (USAN) D03257 Trastuzumab (USAN/INN) D03305 Interferon alfa (NAMALWA) (JP18) D03350 Canertinib dihydrochloride (USAN) D03357 Interferon gamma-1a (genetical recombination) (JAN) D03455 Cetuximab (USAN/INN) D03658 Dasatinib (JAN/INN) D03682 Denileukin diftitox (USAN/INN) D03800 Rebimastat (USAN/INN) D03802 Tanomastat (USAN/INN) D04014 Enzastaurin hydrochloride (JAN/USAN) D04023 Erlotinib hydrochloride (JAN/USAN) D04024 Lapatinib ditosylate (USAN) D04025 Mubritinib (USAN/INN) D04162 Fenretinide (USAN/INN) D04696 Lestaurtinib (USAN/INN) D04862 Masoprocol (USAN/INN) D05029 Midostaurin (JAN/USAN/INN) D05350 Panitumumab (USAN/INN) D05380 Pazopanib hydrochloride (JAN/USAN) D05386 Pegaptanib sodium (JAN/USAN) D05399 Pelitinib (USAN/INN) D05446 Pertuzumab (USAN/INN) D05803 Sargramostim (USP/INN) D05819 Semaxanib (USAN/INN) D06005 Tandutinib (USAN/INN) D06068 Temsirolimus (JAN/USAN/INN) D06272 Sorafenib tosylate (USAN) D06285 Vatalanib (USAN/INN) D06320 Vorinostat (JAN/USAN) D06402 Sunitinib malate (JAN/USAN) D06407 Vandetanib (JAN/USAN/INN) D06409 Bevacizumab (USAN) D06413 Nilotinib hydrochloride hydrate (JAN) D06414 Dasatinib (USAN) D06554 Alvespimycin hydrochloride (USAN) D06563 Belagenpumatucel-L (USAN) D06610 Lapuleucel-T (USAN) D06637 Romidepsin (JAN/USAN/INN) D06678 Motesanib (USAN) D06889 Pegfilgrastim (USAN/INN) D07434 Polyestradiol phosphate (INN) D07741 Zibotentan (JAN/USAN/INN) D07907 Erlotinib (INN) D08066 Imatinib (INN) D08108 Lapatinib (INN) D08524 Sorafenib (USAN/INN) D08552 Sunitinib (INN) D08559 Tamoxifen (INN) D08805 Interferon gamma-n1 (JAN) D08870 Belinostat (USAN/INN) D08881 Cediranib (USAN/INN) D08883 Cediranib maleate (JAN/USAN) D08900 Ridaforolimus (JAN/USAN/INN) D08917 Ezatiostat hydrochloride (USAN) D08947 Motesanib diphosphate (USAN) D08950 Neratinib (USAN/INN) D08953 Nilotinib (USAN/INN) D08956 Omacetaxine mepesuccinate (USAN) D08971 Plerixafor (JAN/USAN/INN) D09328 Cixutumumab (USAN) D09338 Entinostat (JAN/USAN/INN) D09357 Mocetinostat dihydrobromide (USAN) D09574 Aflibercept (USAN/INN) D09604 Dinaciclib (USAN/INN) D09629 Imetelstat (USAN/INN) D09630 Imetelstat sodium (USAN) D09635 Linifanib (USAN/INN) D09641 Mocetinostat (USAN/INN) D09659 Rilotumumab (USAN/INN) D09660 Rindopepimut (USAN) D09683 Tivozanib (USAN/INN) D09689 Varlitinib (USAN/INN) D09690 Varlitinib tosylate (USAN) D09724 Afatinib (USAN/INN) D09728 Bosutinib hydrate (JAN) D09731 Crizotinib (JAN/USAN/INN) D09733 Afatinib dimaleate (USAN) D09746 Dalotuzumab (USAN) D09864 Amuvatinib (USAN/INN) D09865 Amuvatinib hydrochloride (USAN) D09908 Ganitumab (USAN/INN) D09909 Gataparsen (USAN/INN) D09910 Gataparsen sodium (USAN) D09919 Lenvatinib (USAN/INN) D09920 Lenvatinib mesylate (USAN) D09939 Olaratumab (USAN/INN) D09941 Onartuzumab (USAN/INN) D09950 Ponatinib (USAN/INN) D09951 Ponatinib hydrochloride (JAN/USAN) D09955 Quizartinib (USAN/INN) D09956 Quizartinib dihydrochloride (USAN) D09959 Ruxolitinib (USAN/INN) D09960 Ruxolitinib phosphate (JAN/USAN) D09980 Trastuzumab emtansine (USAN/INN) D09992 Vismodegib (USAN/INN) D09996 Vemurafenib (JAN/USAN/INN) D10015 Litgenprostucel-L (USAN) D10019 Panobinostat lactate (JAN) D10031 Zalutumumab (USAN/INN) D10060 Abexinostat (USAN) D10062 Cabozantinib (USAN) D10064 Dabrafenib (USAN) D10076 Olcorolimus (USAN) D10084 Abexinostat hydrochloride (USAN) D10095 Cabozantinib s-malate (USAN) D10102 Crenolanib (USAN) D10103 Crenolanib besylate (USAN) D10104 Dabrafenib mesylate (USAN) D10119 Sonidegib (USAN/INN) D10123 Ficlatuzumab (USAN) D10137 Regorafenib hydrate (JAN) D10138 Regorafenib (USAN/INN) D10164 Sepantronium bromide (JAN/USAN) D10173 Tivantinib (JAN/USAN/INN) D10175 Trametinib (USAN) D10176 Trametinib dimethyl sulfoxide (JAN/USAN) D10189 Pictilisib (USAN/INN) D10190 Tivozanib hydrochloride (USAN) D10218 Enzalutamide (JAN/USAN) D10224 Golvatinib (USAN) D10229 Masitinib (INN) D10242 Lipegfilgrastim (USAN) D10319 Panobinostat (USAN/INN) D10321 Quisinostat (USAN/INN) D10322 Quisinostat hydrochloride (USAN) D10324 Patidegib (USAN/INN) D10325 Patidegib hydrochloride (USAN) D10334 Rebastinib (USAN) D10372 Palbociclib (JAN/USAN) D10381 Afuresertib (USAN/INN) D10382 Afuresertib hydrochloride (USAN) D10396 Nintedanib esylate (USAN) D10399 Rebastinib Tosylate (USAN) D10405 Cobimetinib (USAN/INN) D10410 Vantictumab (USAN/INN) D10423 Ilorasertib (USAN/INN) D10426 Pimasertib (USAN/INN) D10437 Galunisertib (USAN/INN) D10446 Margetuximab (USAN/INN) D10450 Alectinib hydrochloride (JAN) D10464 Firtecan pegol (USAN/INN) D10465 Golvatinib tartrate (USAN) D10481 Nintedanib (USAN/INN) D10486 Pimasertib hydrochloride (USAN) D10542 Alectinib (USAN/INN) D10543 Apitolisib (USAN/INN) D10551 Ceritinib (JAN/USAN/INN) D10552 Dactolisib (USAN/INN) D10555 Duvelisib (USAN/INN) D10560 Idelalisib (JAN/USAN/INN) D10584 Buparlisib (USAN/INN) D10604 Binimetinib (JAN/USAN/INN) D10609 Buparlisib hydrochloride (JAN/USAN) D10615 Cobimetinib fumarate (USAN) D10616 Dactolisib tosylate (USAN) D10635 Gedatolisib (USAN/INN) D10636 Glasdegib (USAN/INN) D10641 Ipatasertib (USAN/INN) D10652 Palbociclib isethionate (USAN) D10671 Taladegib (USAN/INN) D10679 Venetoclax (JAN/USAN/INN) D10688 Abemaciclib (JAN/USAN/INN) D10696 Capmatinib (USAN/INN) D10709 Gilteritinib (USAN/INN) D10717 Napabucasin (JAN/USAN/INN) D10718 Omipalisib (USAN/INN) D10729 Sonidegib phosphate (USAN) D10766 Osimertinib mesylate (USAN) D10797 Copanlisib hydrochloride (USAN) D10798 Copanlisib hydrochloride hydrate (JAN) D10800 Gilteritinib fumarate (JAN/USAN) D10858 Rociletinib (USAN/INN) D10859 Olmutinib (USAN/INN) D10866 Brigatinib (JAN/USAN) D10867 Copanlisib (USAN/INN) D10883 Ribociclib (USAN/INN) D10891 Capmatinib hydrochloride (USAN) D10898 Neratinib maleate D10924 Dezapelisib (USAN/INN) D10926 Entrectinib (JAN/USAN/INN) D10927 Erdafitinib (JAN/USAN/INN) D10958 Naquotinib (USAN/INN) D10977 Remetinostat (USAN/INN) D10979 Ribociclib succinate (USAN) D10981 Rovalpituzumab tesirine (USAN/INN) D10993 Tucidinostat (JAN/USAN/INN) D11011 Alpelisib (JAN/USAN/INN) D11012 Lorlatinib (JAN/USAN/INN) D11032 Plitidepsin (INN) D11038 Ulixertinib (INN) D11040 Apalutamide (JAN/INN) D11045 Darolutamide (JAN/USAN/INN) D11053 Encorafenib (JAN/USAN/INN) D11073 Tepotinib hydrochloride (USAN) D11074 Ipatasertib hydrochloride (JAN) D11107 Glasdegib maleate (JAN) D11115 Olmutinib hydrochloride (USAN) D11117 Rovalpituzumab (USAN) D11125 Modotuximab (USAN/INN) D11126 Navicixizumab (USAN/INN) D11130 Trilaciclib (USAN/INN) D11136 Glesatinib (USAN/INN) D11137 Larotrectinib (USAN/INN) D11138 Larotrectinib sulfate (JAN/USAN) D11139 Savolitinib (JAN/USAN/INN) D11140 Sitravatinib (USAN/INN) D11141 Tucatinib (USAN/INN) D11151 Crenigacestat (USAN/INN) D11182 Tinostamustine (USAN/INN) D11184 Ralaniten (USAN/INN) D11185 Ralaniten acetate (USAN) D11229 Brontictuzumab (USAN/INN) D11234 Emactuzumab (USAN/INN) D11251 Icotinib D11264 Brilanestrant (USAN/INN) D11270 Pexidartinib (USAN/INN) D11271 Pexidartinib hydrochloride (JAN/USAN) D11279 Avapritinib (USAN/INN) D11285 Ravoxertinib (USAN/INN) D11307 Telisotuzumab (USAN) D11323 Umbralisib tosylate (USAN) D11344 Telisotuzumab vedotin (USAN) D11346 Ensartinib (USAN) D11353 Ripretinib (USAN) D11356 Ensartinib hydrochloride (USAN) D11358 Tagraxofusp (USAN/INN) D11371 Capivasertib (JAN/USAN) D11403 Asciminib (USAN/INN) D11404 Asciminib hydrochloride (JAN/USAN) D11409 Miransertib (USAN/INN) D11410 Lifirafenib (USAN/INN) D11411 Lifirafenib maleate (USAN) D11417 Pemigatinib (JAN/USAN/INN) D11430 Nazartinib (USAN/INN) D11434 Nazartinib mesylate (USAN) D11437 Parsaclisib (USAN/INN) D11440 Bimiralisib (USAN/INN) D11442 Nanatinostat (USAN) D11454 Repotrectinib (JAN/USAN) D11455 Lerociclib (USAN) D11461 Derazantinib hydrochloride (USAN) D11501 Samotolisib (USAN) D11506 Parsaclisib hydrochloride (JAN/USAN) D11508 Miransertib mesylate (USAN) D11529 Trastuzumab deruxtecan (USAN/INN) D11541 Sitravatinib malate (USAN) D11589 Infigratinib (USAN/INN) D11599 Zotiraciclib (USAN) D11600 Zotiraciclib citrate (USAN) D11642 Dilpacimab (USAN/INN) D11658 Duvelisib hydrate (JAN) D11663 Onatasertib (USAN) D11669 Bempegaldesleukin (USAN/INN) D11671 Elacestrant (USAN/INN) D11672 Elacestrant hydrochloride (USAN) D11675 Mirdametinib (USAN) D11712 Pralsetinib (USAN/INN) D11713 Selpercatinib (JAN/USAN/INN) D11717 Tepotinib (USAN/INN) D11725 Futibatinib (JAN/USAN/INN) D11727 Voxtalisib (USAN/INN) D11737 Fisogatinib (USAN/INN) D11747 Inbakicept (USAN/INN) D11762 Lucitanib (USAN/INN) D11763 Merestinib (USAN/INN) D11768 Pacritinib (USAN/INN) D11772 Tesevatinib (USAN/INN) D11773 Tesevatinib tosylate (USAN) D11774 Taselisib (USAN/INN) D11775 Tarextumab (USAN/INN) D11786 Vodobatinib (USAN) D11803 Cetuximab sarotalocan (USAN/INN) D11805 Cetuximab sarotalocan sodium (genetical recombination) (JAN) D11821 Nogapendekin alfa (USAN/INN) D11872 Serclutamab (USAN/INN) D11874 Serclutamab talirine (USAN/INN) D11885 Surufatinib (USAN/INN) D11890 Emvododstat (USAN) D11894 Amivantamab (USAN/INN) D11935 Enzastaurin (USAN/INN) D11942 Inavolisib (USAN/INN) D11954 Belzutifan (JAN/USAN/INN) D11961 Giredestrant (USAN/INN) D11969 Mobocertinib succinate (JAN) D11980 Lazertinib (USAN/INN) D11987 Trilaciclib dihydrochloride D12001 Mobocertinib (USAN/INN) D12009 Zandelisib (JAN/USAN/INN) D12011 Zanidatamab (USAN/INN) D12049 Camizestrant (JAN/USAN) D12055 Sotorasib (JAN/USAN) D12059 Temuterkib (USAN) D12060 Temuterkib mesylate (USAN) D12128 Balixafortide (USAN/INN) D12145 Amcenestrant (JAN/USAN/INN) D12175 Olverembatinib (USAN/INN) D12229 Poziotinib (USAN/INN) D12230 Poziotinib hydrochloride (USAN) D12245 Lazertinib mesylate (USAN) D12258 Aumolertinib (USAN/INN) D12259 Aumolertinib mesylate (USAN) D12281 Motixafortide (USAN/INN) D12282 Motixafortide acetate (USAN) D12291 Tovorafenib (USAN/INN) D12301 Adagrasib (USAN/INN) D12303 Deutenzalutamide (USAN) D12304 Elraglusib (USAN) D12307 Pivekimab (USAN) D12316 Bavdegalutamide (USAN) D12330 Zeteletinib (USAN) D12331 Zeteletinib adipate (USAN) D12354 Pralsetinib hydrate (JAN) D12363 Taletrectinib (USAN/INN) D12364 Taletrectinib adipate (USAN) D12394 Inobrodib (USAN) D12399 Sulanemadlin (USAN/INN) D12404 Tasurgratinib (INN) D12405 Tasurgratinib succinate (JAN) D12416 Petosemtamab (USAN/INN) D12424 Davutamig (USAN) D12432 Zurletrectinib (USAN) D12442 Tucatinib ethanolate (JAN) D12444 Nilotinib hydrochloride dihydrate (JAN) D12445 Foscenvivint (JAN/INN) D12457 Tuxobertinib (USAN/INN) D12476 Tuspetinib (USAN/INN) D12506 Sunvozertinib (USAN/INN) D12514 Amdizalisib (USAN/INN) D12515 Avutometinib (USAN/INN) D12526 Catequentinib (USAN/INN) D12531 Nadofaragene firadenovec (USAN/INN) D12534 Avutometinib potassium (USAN) D12537 Catequentinib hydrochloride (USAN) D12545 Tinengotinib (USAN/INN) D12551 Bocodepsin (USAN) D12552 Bocodepsin besylate (USAN) D12557 Elzovantinib (USAN/INN) D12558 Emzadirib (USAN) D12559 Enbezotinib (USAN/INN) D12583 Anvatabart opadotin (USAN/INN) D12584 Anvatabart pactil (USAN/INN) D12600 Bezuclastinib (USAN/INN) D12601 Tegtociclib (USAN) D12625 Pegenzileukin (USAN/INN) D12628 Vepdegestrant (JAN/USAN/INN) D12639 Divarasib (USAN/INN) D12640 Divarasib adipate (USAN) D12641 Emirodatamab (USAN/INN) D12643 Masofaniten (USAN/INN) D12646 Paltimatrectinib (USAN/INN) D12650 Zanzalintinib (USAN/INN) D12651 Zanzalintinib fumarate (USAN) D12705 Gumarontinib hydrate (JAN) D12730 Tigozertinib (USAN) D12768 Ficerafusp alfa (USAN) D12809 Bafisontamab (USAN/INN) D12827 Palazestrant (USAN/INN) D12831 Naporafenib (USAN/INN) D12834 Atirmociclib (USAN) D12836 Risovalisib (INN) D12837 Risovalisib mesilate hydrate (JAN) D12853 Olomorasib (USAN) D12854 Nilotinib laurylsulfate (USAN) D12859 Pebezertinib (USAN) D12865 Beroterkib (USAN) D12866 Gridegalutamide (USAN) D12879 Zongertinib (JAN/USAN/INN) D12883 Sonrotoclax (USAN/INN) D12888 Nogapendekin alfa inbakicept D12921 Tizaterkib (USAN/INN) D12922 Tizaterkib adipate (USAN) D12924 Pocenbrodib (USAN/INN) D12925 Pocenbrodib hydrochloride (USAN) D12928 Vopikitug (USAN/INN) D12943 Giredestrant tartrate (JAN) D12946 Certociclib (USAN) D12947 Claturafenib (USAN) D12956 Firmonertinib (USAN/INN) D12957 Firmonertinib mesylate (USAN) D12982 Rezatapopt (USAN/INN) D12988 Disitamab (USAN/INN) ORGANISM Homo sapiens (human) [GN:hsa] GENE 1630 DCC; DCC netrin 1 receptor [KO:K06765] 836 CASP3; caspase 3 [KO:K02187] [EC:3.4.22.56] 842 CASP9; caspase 9 [KO:K04399] [EC:3.4.22.62] 26060 APPL1; adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 [KO:K08733] 999 CDH1; cadherin 1 [KO:K05689] 1499 CTNNB1; catenin beta 1 [KO:K02105] 29119 CTNNA3; catenin alpha 3 [KO:K05691] 1495 CTNNA1; catenin alpha 1 [KO:K05691] 1496 CTNNA2; catenin alpha 2 [KO:K05691] 8312 AXIN1; axin 1 [KO:K02157] 8313 AXIN2; axin 2 [KO:K04385] 324 APC; APC regulator of WNT signaling pathway [KO:K02085] 10297 APC2; APC regulator of WNT signaling pathway 2 [KO:K02085] 2932 GSK3B; glycogen synthase kinase 3 beta [KO:K03083] [EC:2.7.11.26] 6932 TCF7; transcription factor 7 [KO:K02620] 83439 TCF7L1; transcription factor 7 like 1 [KO:K04490] 6934 TCF7L2; transcription factor 7 like 2 [KO:K04491] 51176 LEF1; lymphoid enhancer binding factor 1 [KO:K04492] 332 BIRC5; baculoviral IAP repeat containing 5 [KO:K08731] 4609 MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377] 595 CCND1; cyclin D1 [KO:K04503] 7471 WNT1; Wnt family member 1 [KO:K03209] 7472 WNT2; Wnt family member 2 [KO:K00182] 7482 WNT2B; Wnt family member 2B [KO:K00182] 7473 WNT3; Wnt family member 3 [KO:K00312] 89780 WNT3A; Wnt family member 3A [KO:K00312] 54361 WNT4; Wnt family member 4 [KO:K00408] 7474 WNT5A; Wnt family member 5A [KO:K00444] 81029 WNT5B; Wnt family member 5B [KO:K00444] 7475 WNT6; Wnt family member 6 [KO:K00445] 7476 WNT7A; Wnt family member 7A [KO:K00572] 7477 WNT7B; Wnt family member 7B [KO:K00572] 7478 WNT8A; Wnt family member 8A [KO:K00714] 7479 WNT8B; Wnt family member 8B [KO:K00714] 7483 WNT9A; Wnt family member 9A [KO:K01064] 7484 WNT9B; Wnt family member 9B [KO:K01064] 7480 WNT10B; Wnt family member 10B [KO:K01357] 80326 WNT10A; Wnt family member 10A [KO:K01357] 7481 WNT11; Wnt family member 11 [KO:K01384] 51384 WNT16; Wnt family member 16 [KO:K01558] 8321 FZD1; frizzled class receptor 1 [KO:K02432] 8324 FZD7; frizzled class receptor 7 [KO:K02432] 2535 FZD2; frizzled class receptor 2 [KO:K02235] 7976 FZD3; frizzled class receptor 3 [KO:K02329] 8322 FZD4; frizzled class receptor 4 [KO:K02354] 7855 FZD5; frizzled class receptor 5 [KO:K02375] 8325 FZD8; frizzled class receptor 8 [KO:K02375] 8323 FZD6; frizzled class receptor 6 [KO:K02376] 11211 FZD10; frizzled class receptor 10 [KO:K02842] 8326 FZD9; frizzled class receptor 9 [KO:K02842] 4041 LRP5; LDL receptor related protein 5 [KO:K03068] 4040 LRP6; LDL receptor related protein 6 [KO:K03068] 1857 DVL3; dishevelled segment polarity protein 3 [KO:K02353] 1856 DVL2; dishevelled segment polarity protein 2 [KO:K02353] 1855 DVL1; dishevelled segment polarity protein 1 [KO:K02353] 10023 FRAT1; FRAT regulator of WNT signaling pathway 1 [KO:K03069] 23401 FRAT2; FRAT regulator of WNT signaling pathway 2 [KO:K03096] 2147 F2; coagulation factor II, thrombin [KO:K01313] [EC:3.4.21.5] 183 AGT; angiotensinogen [KO:K09821] 2149 F2R; coagulation factor II thrombin receptor [KO:K03914] 9002 F2RL3; F2R like thrombin or trypsin receptor 3 [KO:K04236] 1902 LPAR1; lysophosphatidic acid receptor 1 [KO:K04289] 9170 LPAR2; lysophosphatidic acid receptor 2 [KO:K04291] 23566 LPAR3; lysophosphatidic acid receptor 3 [KO:K04294] 2846 LPAR4; lysophosphatidic acid receptor 4 [KO:K04275] 57121 LPAR5; lysophosphatidic acid receptor 5 [KO:K08390] 10161 LPAR6; lysophosphatidic acid receptor 6 [KO:K04273] 185 AGTR1; angiotensin II receptor type 1 [KO:K04166] 2768 GNA12; G protein subunit alpha 12 [KO:K04346] 10672 GNA13; G protein subunit alpha 13 [KO:K04639] 23365 ARHGEF12; Rho guanine nucleotide exchange factor 12 [KO:K07532] 9826 ARHGEF11; Rho guanine nucleotide exchange factor 11 [KO:K12331] 9138 ARHGEF1; Rho guanine nucleotide exchange factor 1 [KO:K12330] 57449 PLEKHG5; pleckstrin homology and RhoGEF domain containing G5 [KO:K19464] 387 RHOA; ras homolog family member A [KO:K04513] 6093 ROCK1; Rho associated coiled-coil containing protein kinase 1 [KO:K04514] [EC:2.7.11.39] 9475 ROCK2; Rho associated coiled-coil containing protein kinase 2 [KO:K17388] [EC:2.7.11.39] 6387 CXCL12; C-X-C motif chemokine ligand 12 [KO:K10031] 7852 CXCR4; C-X-C motif chemokine receptor 4 [KO:K04189] 2770 GNAI1; G protein subunit alpha i1 [KO:K04630] 2773 GNAI3; G protein subunit alpha i3 [KO:K04630] 2771 GNAI2; G protein subunit alpha i2 [KO:K04630] 5731 PTGER1; prostaglandin E receptor 1 [KO:K04258] 5732 PTGER2; prostaglandin E receptor 2 [KO:K04259] 5733 PTGER3; prostaglandin E receptor 3 [KO:K04260] 5734 PTGER4; prostaglandin E receptor 4 [KO:K04261] 2778 GNAS; GNAS complex locus [KO:K04632] 107 ADCY1; adenylate cyclase 1 [KO:K08041] [EC:4.6.1.1] 108 ADCY2; adenylate cyclase 2 [KO:K08042] [EC:4.6.1.1] 109 ADCY3; adenylate cyclase 3 [KO:K08043] [EC:4.6.1.1] 196883 ADCY4; adenylate cyclase 4 [KO:K08044] [EC:4.6.1.1] 111 ADCY5; adenylate cyclase 5 [KO:K08045] [EC:4.6.1.1] 112 ADCY6; adenylate cyclase 6 [KO:K08046] [EC:4.6.1.1] 113 ADCY7; adenylate cyclase 7 [KO:K08047] [EC:4.6.1.1] 114 ADCY8; adenylate cyclase 8 [KO:K08048] [EC:4.6.1.1] 115 ADCY9; adenylate cyclase 9 [KO:K08049] [EC:4.6.1.1] 5566 PRKACA; protein kinase cAMP-activated catalytic subunit alpha [KO:K04345] [EC:2.7.11.11] 5567 PRKACB; protein kinase cAMP-activated catalytic subunit beta [KO:K04345] [EC:2.7.11.11] 5568 PRKACG; protein kinase cAMP-activated catalytic subunit gamma [KO:K04345] [EC:2.7.11.11] 2782 GNB1; G protein subunit beta 1 [KO:K04536] 2783 GNB2; G protein subunit beta 2 [KO:K04537] 2784 GNB3; G protein subunit beta 3 [KO:K07825] 59345 GNB4; G protein subunit beta 4 [KO:K04538] 10681 GNB5; G protein subunit beta 5 [KO:K04539] 54331 GNG2; G protein subunit gamma 2 [KO:K07826] 2785 GNG3; G protein subunit gamma 3 [KO:K04540] 2786 GNG4; G protein subunit gamma 4 [KO:K04541] 2787 GNG5; G protein subunit gamma 5 [KO:K04542] 2788 GNG7; G protein subunit gamma 7 [KO:K04543] 94235 GNG8; G protein subunit gamma 8 [KO:K04544] 2790 GNG10; G protein subunit gamma 10 [KO:K04545] 2791 GNG11; G protein subunit gamma 11 [KO:K04546] 55970 GNG12; G protein subunit gamma 12 [KO:K04347] 51764 GNG13; G protein subunit gamma 13 [KO:K04547] 2792 GNGT1; G protein subunit gamma transducin 1 [KO:K04548] 2793 GNGT2; G protein subunit gamma transducin 2 [KO:K04549] 1284 COL4A2; collagen type IV alpha 2 chain [KO:K06237] 1286 COL4A4; collagen type IV alpha 4 chain [KO:K06237] 1288 COL4A6; collagen type IV alpha 6 chain [KO:K06237] 1282 COL4A1; collagen type IV alpha 1 chain [KO:K06237] 1287 COL4A5; collagen type IV alpha 5 chain [KO:K06237] 1285 COL4A3; collagen type IV alpha 3 chain [KO:K06237] 284217 LAMA1; laminin subunit alpha 1 [KO:K05637] 3908 LAMA2; laminin subunit alpha 2 [KO:K05637] 3909 LAMA3; laminin subunit alpha 3 [KO:K06240] 3911 LAMA5; laminin subunit alpha 5 [KO:K06240] 3910 LAMA4; laminin subunit alpha 4 [KO:K06241] 3912 LAMB1; laminin subunit beta 1 [KO:K05636] 3913 LAMB2; laminin subunit beta 2 [KO:K06243] 3914 LAMB3; laminin subunit beta 3 [KO:K06244] 22798 LAMB4; laminin subunit beta 4 [KO:K06245] 3915 LAMC1; laminin subunit gamma 1 [KO:K05635] 3918 LAMC2; laminin subunit gamma 2 [KO:K06246] 10319 LAMC3; laminin subunit gamma 3 [KO:K06247] 2335 FN1; fibronectin 1 [KO:K05717] 3673 ITGA2; integrin subunit alpha 2 [KO:K06481] 3674 ITGA2B; integrin subunit alpha 2b [KO:K06476] 3675 ITGA3; integrin subunit alpha 3 [KO:K06482] 3655 ITGA6; integrin subunit alpha 6 [KO:K06485] 3685 ITGAV; integrin subunit alpha V [KO:K06487] 3688 ITGB1; integrin subunit beta 1 [KO:K05719] 5747 PTK2; protein tyrosine kinase 2 [KO:K05725] [EC:2.7.10.2] 5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922] [EC:2.7.1.153] 5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922] [EC:2.7.1.153] 5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922] [EC:2.7.1.153] 5295 PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649] 5296 PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649] 8503 PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649] 110117499 P3R3URF-PIK3R3; P3R3URF-PIK3R3 readthrough [KO:K02649] 5728 PTEN; phosphatase and tensin homolog [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67] 4824 NKX3-1; NK3 homeobox 1 [KO:K09348] 207 AKT1; AKT serine/threonine kinase 1 [KO:K04456] [EC:2.7.11.1] 208 AKT2; AKT serine/threonine kinase 2 [KO:K04456] [EC:2.7.11.1] 10000 AKT3; AKT serine/threonine kinase 3 [KO:K04456] [EC:2.7.11.1] 1147 CHUK; component of inhibitor of nuclear factor kappa B kinase complex [KO:K04467] [EC:2.7.11.10] 3551 IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta [KO:K07209] [EC:2.7.11.10] 8517 IKBKG; inhibitor of nuclear factor kappa B kinase regulatory subunit gamma [KO:K07210] 4792 NFKBIA; NFKB inhibitor alpha [KO:K04734] 4790 NFKB1; nuclear factor kappa B subunit 1 [KO:K02580] 4791 NFKB2; nuclear factor kappa B subunit 2 [KO:K04469] 5970 RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735] 5743 PTGS2; prostaglandin-endoperoxide synthase 2 [KO:K11987] [EC:1.14.99.1] 4843 NOS2; nitric oxide synthase 2 [KO:K13241] [EC:1.14.13.39] 596 BCL2; BCL2 apoptosis regulator [KO:K02161] 329 BIRC2; baculoviral IAP repeat containing 2 [KO:K16060] 330 BIRC3; baculoviral IAP repeat containing 3 [KO:K16060] 331 XIAP; X-linked inhibitor of apoptosis [KO:K04725] [EC:2.3.2.27] 79444 BIRC7; baculoviral IAP repeat containing 7 [KO:K16061] 598 BCL2L1; BCL2 like 1 [KO:K04570] 7185 TRAF1; TNF receptor associated factor 1 [KO:K03172] 7186 TRAF2; TNF receptor associated factor 2 [KO:K03173] [EC:2.3.2.27] 7187 TRAF3; TNF receptor associated factor 3 [KO:K03174] 9618 TRAF4; TNF receptor associated factor 4 [KO:K09848] 7188 TRAF5; TNF receptor associated factor 5 [KO:K09849] 7189 TRAF6; TNF receptor associated factor 6 [KO:K03175] [EC:2.3.2.27] 2475 MTOR; mechanistic target of rapamycin kinase [KO:K07203] [EC:2.7.11.1] 6198 RPS6KB1; ribosomal protein S6 kinase B1 [KO:K04688] [EC:2.7.11.1] 6199 RPS6KB2; ribosomal protein S6 kinase B2 [KO:K04688] [EC:2.7.11.1] 572 BAD; BCL2 associated agonist of cell death [KO:K02158] 2308 FOXO1; forkhead box O1 [KO:K07201] 4193 MDM2; MDM2 proto-oncogene [KO:K06643] [EC:2.3.2.27] 7157 TP53; tumor protein p53 [KO:K04451] 1027 CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624] 1026 CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625] 613 BCR; BCR activator of RhoGEF and GTPase [KO:K08878] [EC:2.7.11.1] 25 ABL1; ABL proto-oncogene 1, non-receptor tyrosine kinase [KO:K06619] [EC:2.7.10.2] 1398 CRK; CRK proto-oncogene, adaptor protein [KO:K04438] 1399 CRKL; CRK like proto-oncogene, adaptor protein [KO:K04438] 867 CBL; Cbl proto-oncogene [KO:K04707] [EC:2.3.2.27] 6776 STAT5A; signal transducer and activator of transcription 5A [KO:K11223] 6777 STAT5B; signal transducer and activator of transcription 5B [KO:K11224] 5292 PIM1; Pim-1 proto-oncogene, serine/threonine kinase [KO:K04702] [EC:2.7.11.1] 11040 PIM2; Pim-2 proto-oncogene, serine/threonine kinase [KO:K08806] [EC:2.7.11.1] 3827 KNG1; kininogen 1 [KO:K03898] 1906 EDN1; endothelin 1 [KO:K16366] 623 BDKRB1; bradykinin receptor B1 [KO:K03915] 624 BDKRB2; bradykinin receptor B2 [KO:K03916] 1909 EDNRA; endothelin receptor type A [KO:K04197] 1910 EDNRB; endothelin receptor type B [KO:K04198] 2776 GNAQ; G protein subunit alpha q [KO:K04634] 2767 GNA11; G protein subunit alpha 11 [KO:K04635] 23236 PLCB1; phospholipase C beta 1 [KO:K05858] [EC:3.1.4.11] 5330 PLCB2; phospholipase C beta 2 [KO:K05858] [EC:3.1.4.11] 5331 PLCB3; phospholipase C beta 3 [KO:K05858] [EC:3.1.4.11] 5332 PLCB4; phospholipase C beta 4 [KO:K05858] [EC:3.1.4.11] 5578 PRKCA; protein kinase C alpha [KO:K02677] [EC:2.7.11.13] 5579 PRKCB; protein kinase C beta [KO:K19662] [EC:2.7.11.13] 5582 PRKCG; protein kinase C gamma [KO:K19663] [EC:2.7.11.13] 3558 IL2; interleukin 2 [KO:K05429] 3562 IL3; interleukin 3 [KO:K04736] 3565 IL4; interleukin 4 [KO:K05430] 3567 IL5; interleukin 5 [KO:K05428] 3569 IL6; interleukin 6 [KO:K05405] 3574 IL7; interleukin 7 [KO:K05431] 3592 IL12A; interleukin 12A [KO:K05406] 3593 IL12B; interleukin 12B [KO:K05425] 3596 IL13; interleukin 13 [KO:K05435] 3600 IL15; interleukin 15 [KO:K05433] 51561 IL23A; interleukin 23 subunit alpha [KO:K05426] 2056 EPO; erythropoietin [KO:K05437] 3439 IFNA1; interferon alpha 1 [KO:K05414] 3440 IFNA2; interferon alpha 2 [KO:K05414] 3441 IFNA4; interferon alpha 4 [KO:K05414] 3442 IFNA5; interferon alpha 5 [KO:K05414] 3443 IFNA6; interferon alpha 6 [KO:K05414] 3444 IFNA7; interferon alpha 7 [KO:K05414] 3445 IFNA8; interferon alpha 8 [KO:K05414] 3446 IFNA10; interferon alpha 10 [KO:K05414] 3447 IFNA13; interferon alpha 13 [KO:K05414] 3448 IFNA14; interferon alpha 14 [KO:K05414] 3449 IFNA16; interferon alpha 16 [KO:K05414] 3451 IFNA17; interferon alpha 17 [KO:K05414] 3452 IFNA21; interferon alpha 21 [KO:K05414] 3458 IFNG; interferon gamma [KO:K04687] 3559 IL2RA; interleukin 2 receptor subunit alpha [KO:K05068] 3560 IL2RB; interleukin 2 receptor subunit beta [KO:K05069] 3561 IL2RG; interleukin 2 receptor subunit gamma [KO:K05070] 3563 IL3RA; interleukin 3 receptor subunit alpha [KO:K04737] 3566 IL4R; interleukin 4 receptor [KO:K05071] 1439 CSF2RB; colony stimulating factor 2 receptor subunit beta [KO:K04738] 3568 IL5RA; interleukin 5 receptor subunit alpha [KO:K05067] 3570 IL6R; interleukin 6 receptor [KO:K05055] 3572 IL6ST; interleukin 6 cytokine family signal transducer [KO:K05060] 3575 IL7R; interleukin 7 receptor [KO:K05072] 3594 IL12RB1; interleukin 12 receptor subunit beta 1 [KO:K05063] 3595 IL12RB2; interleukin 12 receptor subunit beta 2 [KO:K05064] 3597 IL13RA1; interleukin 13 receptor subunit alpha 1 [KO:K05076] 3601 IL15RA; interleukin 15 receptor subunit alpha [KO:K05074] 149233 IL23R; interleukin 23 receptor [KO:K05065] 2057 EPOR; erythropoietin receptor [KO:K05079] 3454 IFNAR1; interferon alpha and beta receptor subunit 1 [KO:K05130] 3455 IFNAR2; interferon alpha and beta receptor subunit 2 [KO:K05131] 3459 IFNGR1; interferon gamma receptor 1 [KO:K05132] 3460 IFNGR2; interferon gamma receptor 2 [KO:K05133] 27436 EML4; EMAP like 4 [KO:K15420] 238 ALK; ALK receptor tyrosine kinase [KO:K05119] [EC:2.7.10.1] 10125 RASGRP1; RAS guanyl releasing protein 1 [KO:K04350] 10235 RASGRP2; RAS guanyl releasing protein 2 [KO:K12361] 25780 RASGRP3; RAS guanyl releasing protein 3 [KO:K12362] 115727 RASGRP4; RAS guanyl releasing protein 4 [KO:K12363] 3716 JAK1; Janus kinase 1 [KO:K11217] [EC:2.7.10.2] 3717 JAK2; Janus kinase 2 [KO:K04447] [EC:2.7.10.2] 3718 JAK3; Janus kinase 3 [KO:K11218] [EC:2.7.10.2] 6774 STAT3; signal transducer and activator of transcription 3 [KO:K04692] 6772 STAT1; signal transducer and activator of transcription 1 [KO:K11220] 6773 STAT2; signal transducer and activator of transcription 2 [KO:K11221] 6775 STAT4; signal transducer and activator of transcription 4 [KO:K11222] 6778 STAT6; signal transducer and activator of transcription 6 [KO:K11225] 7422 VEGFA; vascular endothelial growth factor A [KO:K05448] 7423 VEGFB; vascular endothelial growth factor B [KO:K16858] 5228 PGF; placental growth factor [KO:K16859] 7424 VEGFC; vascular endothelial growth factor C [KO:K05449] 2277 VEGFD; vascular endothelial growth factor D [KO:K05449] 7039 TGFA; transforming growth factor alpha [KO:K08774] 1950 EGF; epidermal growth factor [KO:K04357] 1956 EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1] 2064 ERBB2; erb-b2 receptor tyrosine kinase 2 [KO:K05083] [EC:2.7.10.1] 5154 PDGFA; platelet derived growth factor subunit A [KO:K04359] 5155 PDGFB; platelet derived growth factor subunit B [KO:K17386] 5156 PDGFRA; platelet derived growth factor receptor alpha [KO:K04363] [EC:2.7.10.1] 5159 PDGFRB; platelet derived growth factor receptor beta [KO:K05089] [EC:2.7.10.1] 3479 IGF1; insulin like growth factor 1 [KO:K05459] 3481 IGF2; insulin like growth factor 2 [KO:K13769] 3480 IGF1R; insulin like growth factor 1 receptor [KO:K05087] [EC:2.7.10.1] 4254 KITLG; KIT ligand [KO:K05461] 3815 KIT; KIT proto-oncogene, receptor tyrosine kinase [KO:K05091] [EC:2.7.10.1] 2323 FLT3LG; fms related receptor tyrosine kinase 3 ligand [KO:K05454] 2322 FLT3; fms related receptor tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1] 3082 HGF; hepatocyte growth factor [KO:K05460] 4233 MET; MET proto-oncogene, receptor tyrosine kinase [KO:K05099] [EC:2.7.10.1] 2246 FGF1; fibroblast growth factor 1 [KO:K18496] 2247 FGF2; fibroblast growth factor 2 [KO:K18497] 2248 FGF3; fibroblast growth factor 3 [KO:K04358] 2249 FGF4; fibroblast growth factor 4 [KO:K04358] 8822 FGF17; fibroblast growth factor 17 [KO:K04358] 2251 FGF6; fibroblast growth factor 6 [KO:K04358] 2252 FGF7; fibroblast growth factor 7 [KO:K04358] 2253 FGF8; fibroblast growth factor 8 [KO:K04358] 2254 FGF9; fibroblast growth factor 9 [KO:K04358] 2255 FGF10; fibroblast growth factor 10 [KO:K04358] 8823 FGF16; fibroblast growth factor 16 [KO:K04358] 2250 FGF5; fibroblast growth factor 5 [KO:K04358] 8817 FGF18; fibroblast growth factor 18 [KO:K04358] 26281 FGF20; fibroblast growth factor 20 [KO:K04358] 27006 FGF22; fibroblast growth factor 22 [KO:K04358] 9965 FGF19; fibroblast growth factor 19 [KO:K22603] 26291 FGF21; fibroblast growth factor 21 [KO:K22429] 8074 FGF23; fibroblast growth factor 23 [KO:K22428] 2260 FGFR1; fibroblast growth factor receptor 1 [KO:K04362] [EC:2.7.10.1] 2263 FGFR2; fibroblast growth factor receptor 2 [KO:K05093] [EC:2.7.10.1] 2261 FGFR3; fibroblast growth factor receptor 3 [KO:K05094] [EC:2.7.10.1] 2264 FGFR4; fibroblast growth factor receptor 4 [KO:K05095] [EC:2.7.10.1] 2885 GRB2; growth factor receptor bound protein 2 [KO:K04364] 6654 SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099] 6655 SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099] 3265 HRAS; HRas proto-oncogene, GTPase [KO:K02833] 3845 KRAS; KRAS proto-oncogene, GTPase [KO:K07827] 4893 NRAS; NRAS proto-oncogene, GTPase [KO:K07828] 369 ARAF; A-Raf proto-oncogene, serine/threonine kinase [KO:K08845] [EC:2.7.11.1] 673 BRAF; B-Raf proto-oncogene, serine/threonine kinase [KO:K04365] [EC:2.7.11.1] 5894 RAF1; Raf-1 proto-oncogene, serine/threonine kinase [KO:K04366] [EC:2.7.11.1] 5604 MAP2K1; mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2] 5605 MAP2K2; mitogen-activated protein kinase kinase 2 [KO:K04369] [EC:2.7.12.2] 5594 MAPK1; mitogen-activated protein kinase 1 [KO:K04371] [EC:2.7.11.24] 5595 MAPK3; mitogen-activated protein kinase 3 [KO:K04371] [EC:2.7.11.24] 3725 JUN; Jun proto-oncogene, AP-1 transcription factor subunit [KO:K04448] 2353 FOS; Fos proto-oncogene, AP-1 transcription factor subunit [KO:K04379] 2113 ETS1; ETS proto-oncogene 1, transcription factor [KO:K02678] 4312 MMP1; matrix metallopeptidase 1 [KO:K01388] [EC:3.4.24.7] 4313 MMP2; matrix metallopeptidase 2 [KO:K01398] [EC:3.4.24.24] 4318 MMP9; matrix metallopeptidase 9 [KO:K01403] [EC:3.4.24.35] 3576 CXCL8; C-X-C motif chemokine ligand 8 [KO:K10030] 1019 CDK4; cyclin dependent kinase 4 [KO:K02089] [EC:2.7.11.22] 9252 RPS6KA5; ribosomal protein S6 kinase A5 [KO:K04445] [EC:2.7.11.1] 5979 RET; ret proto-oncogene [KO:K05126] [EC:2.7.10.1] 8030 CCDC6; coiled-coil domain containing 6 [KO:K09288] 8031 NCOA4; nuclear receptor coactivator 4 [KO:K09289] 4914 NTRK1; neurotrophic receptor tyrosine kinase 1 [KO:K03176] [EC:2.7.10.1] 7170 TPM3; tropomyosin 3 [KO:K09290] 7175 TPR; translocated promoter region, nuclear basket protein [KO:K09291] 10342 TFG; trafficking from ER to golgi regulator [KO:K09292] 11186 RASSF1; Ras association domain family member 1 [KO:K09850] 83593 RASSF5; Ras association domain family member 5 [KO:K08015] 6789 STK4; serine/threonine kinase 4 [KO:K04411] 1612 DAPK1; death associated protein kinase 1 [KO:K08803] [EC:2.7.11.1] 1613 DAPK3; death associated protein kinase 3 [KO:K08803] [EC:2.7.11.1] 23604 DAPK2; death associated protein kinase 2 [KO:K08803] [EC:2.7.11.1] 5335 PLCG1; phospholipase C gamma 1 [KO:K01116] [EC:3.1.4.11] 5336 PLCG2; phospholipase C gamma 2 [KO:K05859] [EC:3.1.4.11] 2002 ELK1; ETS transcription factor ELK1 [KO:K04375] 810 CALML3; calmodulin like 3 [KO:K02183] 805 CALM2; calmodulin 2 [KO:K02183] 808 CALM3; calmodulin 3 [KO:K02183] 801 CALM1; calmodulin 1 [KO:K02183] 163688 CALML6; calmodulin like 6 [KO:K02183] 51806 CALML5; calmodulin like 5 [KO:K02183] 91860 CALML4; calmodulin like 4 [KO:K02183] 815 CAMK2A; calcium/calmodulin dependent protein kinase II alpha [KO:K04515] [EC:2.7.11.17] 817 CAMK2D; calcium/calmodulin dependent protein kinase II delta [KO:K04515] [EC:2.7.11.17] 816 CAMK2B; calcium/calmodulin dependent protein kinase II beta [KO:K04515] [EC:2.7.11.17] 818 CAMK2G; calcium/calmodulin dependent protein kinase II gamma [KO:K04515] [EC:2.7.11.17] 5900 RALGDS; ral guanine nucleotide dissociation stimulator [KO:K08732] 5898 RALA; RAS like proto-oncogene A [KO:K07834] 5899 RALB; RAS like proto-oncogene B [KO:K07835] 10928 RALBP1; ralA binding protein 1 [KO:K08773] 998 CDC42; cell division cycle 42 [KO:K04393] 5879 RAC1; Rac family small GTPase 1 [KO:K04392] 5880 RAC2; Rac family small GTPase 2 [KO:K07860] 5881 RAC3; Rac family small GTPase 3 [KO:K07861] 5337 PLD1; phospholipase D1 [KO:K01115] [EC:3.1.4.4] 5338 PLD2; phospholipase D2 [KO:K01115] [EC:3.1.4.4] 5599 MAPK8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24] 5602 MAPK10; mitogen-activated protein kinase 10 [KO:K04440] [EC:2.7.11.24] 5601 MAPK9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24] 7849 PAX8; paired box 8 [KO:K09293] 5468 PPARG; peroxisome proliferator activated receptor gamma [KO:K08530] 6256 RXRA; retinoid X receptor alpha [KO:K08524] 6257 RXRB; retinoid X receptor beta [KO:K08525] 6258 RXRG; retinoid X receptor gamma [KO:K08526] 5915 RARB; retinoic acid receptor beta [KO:K08528] 2099 ESR1; estrogen receptor 1 [KO:K08550] 2100 ESR2; estrogen receptor 2 [KO:K08551] 8648 NCOA1; nuclear receptor coactivator 1 [KO:K09101] [EC:2.3.1.48] 8202 NCOA3; nuclear receptor coactivator 3 [KO:K11256] [EC:2.3.1.48] 6667 SP1; Sp1 transcription factor [KO:K04684] 5467 PPARD; peroxisome proliferator activated receptor delta [KO:K04504] 3728 JUP; junction plakoglobin [KO:K10056] 7704 ZBTB16; zinc finger and BTB domain containing 16 [KO:K10055] 5914 RARA; retinoic acid receptor alpha [KO:K08527] 890 CCNA2; cyclin A2 [KO:K06627] 8900 CCNA1; cyclin A1 [KO:K06627] 5371 PML; PML nuclear body scaffold [KO:K10054] [EC:2.3.2.-] 861 RUNX1; RUNX family transcription factor 1 [KO:K08367] 862 RUNX1T1; RUNX1 partner transcriptional co-repressor 1 [KO:K10053] 6688 SPI1; Spi-1 proto-oncogene [KO:K09438] 1050 CEBPA; CCAAT enhancer binding protein alpha [KO:K09055] 1438 CSF2RA; colony stimulating factor 2 receptor subunit alpha [KO:K05066] 1441 CSF3R; colony stimulating factor 3 receptor [KO:K05061] 1436 CSF1R; colony stimulating factor 1 receptor [KO:K05090] [EC:2.7.10.1] 1029 CDKN2A; cyclin dependent kinase inhibitor 2A [KO:K06621] 1869 E2F1; E2F transcription factor 1 [KO:K17454] 1870 E2F2; E2F transcription factor 2 [KO:K09389] 1871 E2F3; E2F transcription factor 3 [KO:K06620] 4149 MAX; MYC associated factor X [KO:K04453] 7709 ZBTB17; zinc finger and BTB domain containing 17 [KO:K10500] 1030 CDKN2B; cyclin dependent kinase inhibitor 2B [KO:K04685] 1021 CDK6; cyclin dependent kinase 6 [KO:K02091] [EC:2.7.11.22] 894 CCND2; cyclin D2 [KO:K10151] 896 CCND3; cyclin D3 [KO:K10152] 1163 CKS1B; CDC28 protein kinase regulatory subunit 1B [KO:K02219] 1164 CKS2; CDC28 protein kinase regulatory subunit 2 [KO:K02219] 6500 SKP1; S-phase kinase associated protein 1 [KO:K03094] 8454 CUL1; cullin 1 [KO:K03347] 9978 RBX1; ring-box 1 [KO:K03868] [EC:2.3.2.32] 6502 SKP2; S-phase kinase associated protein 2 [KO:K03875] 1017 CDK2; cyclin dependent kinase 2 [KO:K02206] [EC:2.7.11.22] 898 CCNE1; cyclin E1 [KO:K06626] 9134 CCNE2; cyclin E2 [KO:K06626] 5925 RB1; RB transcriptional corepressor 1 [KO:K06618] 1647 GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402] 4616 GADD45B; growth arrest and DNA damage inducible beta [KO:K04402] 10912 GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402] 581 BAX; BCL2 associated X, apoptosis regulator [KO:K02159] 578 BAK1; BCL2 antagonist/killer 1 [KO:K14021] 1643 DDB2; damage specific DNA binding protein 2 [KO:K10140] 51426 POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7] 7015 TERT; telomerase reverse transcriptase [KO:K11126] [EC:2.7.7.49] 7012 TERC; telomerase RNA component [KO:K22183] 4286 MITF; melanocyte inducing transcription factor [KO:K09455] 7040 TGFB1; transforming growth factor beta 1 [KO:K13375] 7042 TGFB2; transforming growth factor beta 2 [KO:K13376] 7043 TGFB3; transforming growth factor beta 3 [KO:K13377] 7046 TGFBR1; transforming growth factor beta receptor 1 [KO:K04674] [EC:2.7.11.30] 7048 TGFBR2; transforming growth factor beta receptor 2 [KO:K04388] [EC:2.7.11.30] 4087 SMAD2; SMAD family member 2 [KO:K04500] 4088 SMAD3; SMAD family member 3 [KO:K23605] 4089 SMAD4; SMAD family member 4 [KO:K04501] 2122 MECOM; MDS1 and EVI1 complex locus [KO:K04462] [EC:2.1.1.367] 1487 CTBP1; C-terminal binding protein 1 [KO:K04496] [EC:1.1.1.428] 1488 CTBP2; C-terminal binding protein 2 [KO:K04496] [EC:1.1.1.428] 3065 HDAC1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98] 3066 HDAC2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98] 4292 MLH1; mutL homolog 1 [KO:K08734] 4436 MSH2; mutS homolog 2 [KO:K08735] 4437 MSH3; mutS homolog 3 [KO:K08736] 2956 MSH6; mutS homolog 6 [KO:K08737] 675 BRCA2; BRCA2 DNA repair associated [KO:K08775] 5888 RAD51; RAD51 recombinase [KO:K04482] 356 FASLG; Fas ligand [KO:K04389] 355 FAS; Fas cell surface death receptor [KO:K04390] 8772 FADD; Fas associated via death domain [KO:K02373] 841 CASP8; caspase 8 [KO:K04398] [EC:3.4.22.61] 637 BID; BH3 interacting domain death agonist [KO:K04726] 5366 PMAIP1; phorbol-12-myristate-13-acetate-induced protein 1 [KO:K10131] 27113 BBC3; BCL2 binding component 3 [KO:K10132] 10018 BCL2L11; BCL2 like 11 [KO:K16341] 54205 CYCS; cytochrome c, somatic [KO:K08738] 317 APAF1; apoptotic peptidase activating factor 1 [KO:K02084] 840 CASP7; caspase 7 [KO:K04397] [EC:3.4.22.60] 9817 KEAP1; kelch like ECH associated protein 1 [KO:K10456] 4780 NFE2L2; NFE2 like bZIP transcription factor 2 [KO:K05638] 3162 HMOX1; heme oxygenase 1 [KO:K00510] [EC:1.14.14.18] 1728 NQO1; NAD(P)H quinone dehydrogenase 1 [KO:K00355] [EC:1.6.5.2] 221357 GSTA5; glutathione S-transferase alpha 5 [KO:K00799] [EC:2.5.1.18] 2939 GSTA2; glutathione S-transferase alpha 2 [KO:K00799] [EC:2.5.1.18] 2941 GSTA4; glutathione S-transferase alpha 4 [KO:K00799] [EC:2.5.1.18] 119391 GSTO2; glutathione S-transferase omega 2 [KO:K00799] [EC:2.5.1.18] 2948 GSTM4; glutathione S-transferase mu 4 [KO:K00799] [EC:2.5.1.18] 2953 GSTT2; glutathione S-transferase theta 2 (gene/pseudogene) [KO:K00799] [EC:2.5.1.18] 2952 GSTT1; glutathione S-transferase theta 1 [KO:K00799] [EC:2.5.1.18] 2947 GSTM3; glutathione S-transferase mu 3 [KO:K00799] [EC:2.5.1.18] 4257 MGST1; microsomal glutathione S-transferase 1 [KO:K00799] [EC:2.5.1.18] 4259 MGST3; microsomal glutathione S-transferase 3 [KO:K00799] [EC:2.5.1.18] 2944 GSTM1; glutathione S-transferase mu 1 [KO:K00799] [EC:2.5.1.18] 2949 GSTM5; glutathione S-transferase mu 5 [KO:K00799] [EC:2.5.1.18] 4258 MGST2; microsomal glutathione S-transferase 2 [KO:K00799] [EC:2.5.1.18] 2938 GSTA1; glutathione S-transferase alpha 1 [KO:K00799] [EC:2.5.1.18] 2946 GSTM2; glutathione S-transferase mu 2 [KO:K00799] [EC:2.5.1.18] 2940 GSTA3; glutathione S-transferase alpha 3 [KO:K00799] [EC:2.5.1.18] 9446 GSTO1; glutathione S-transferase omega 1 [KO:K00799] [EC:2.5.1.18] 653689 GSTT2B; glutathione S-transferase theta 2B [KO:K00799] [EC:2.5.1.18] 25774 GSTT4; glutathione S-transferase theta 4 [KO:K00799] [EC:2.5.1.18] 2950 GSTP1; glutathione S-transferase pi 1 [KO:K23790] [EC:2.5.1.18] 7296 TXNRD1; thioredoxin reductase 1 [KO:K22182] [EC:1.8.1.9] 114112 TXNRD3; thioredoxin reductase 3 [KO:K22182] [EC:1.8.1.9] 10587 TXNRD2; thioredoxin reductase 2 [KO:K22182] [EC:1.8.1.9] 7428 VHL; von Hippel-Lindau tumor suppressor [KO:K03871] 6921 ELOC; elongin C [KO:K03872] 6923 ELOB; elongin B [KO:K03873] 8453 CUL2; cullin 2 [KO:K03870] 54583 EGLN1; egl-9 family hypoxia inducible factor 1 [KO:K09592] [EC:1.14.11.29] 112399 EGLN3; egl-9 family hypoxia inducible factor 3 [KO:K09592] [EC:1.14.11.29] 112398 EGLN2; egl-9 family hypoxia inducible factor 2 [KO:K09592] [EC:1.14.11.29] 2271 FH; fumarate hydratase [KO:K01679] [EC:4.2.1.2] 3091 HIF1A; hypoxia inducible factor 1 subunit alpha [KO:K08268] 2034 EPAS1; endothelial PAS domain protein 1 [KO:K09095] 405 ARNT; aryl hydrocarbon receptor nuclear translocator [KO:K09097] 9915 ARNT2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589] 1387 CREBBP; CREB binding protein [KO:K04498] [EC:2.3.1.48] 2033 EP300; E1A binding protein p300 [KO:K04498] [EC:2.3.1.48] 6513 SLC2A1; solute carrier family 2 member 1 [KO:K07299] 182 JAG1; jagged canonical Notch ligand 1 [KO:K06052] 3714 JAG2; jagged canonical Notch ligand 2 [KO:K21635] 10683 DLL3; delta like canonical Notch ligand 3 [KO:K06051] 28514 DLL1; delta like canonical Notch ligand 1 [KO:K06051] 54567 DLL4; delta like canonical Notch ligand 4 [KO:K06051] 4851 NOTCH1; notch receptor 1 [KO:K02599] 4853 NOTCH2; notch receptor 2 [KO:K20994] 4854 NOTCH3; notch receptor 3 [KO:K20995] 4855 NOTCH4; notch receptor 4 [KO:K20996] 3280 HES1; hes family bHLH transcription factor 1 [KO:K06054] 388585 HES5; hes family bHLH transcription factor 5 [KO:K06055] 26508 HEYL; hes related family bHLH transcription factor with YRPW motif like [KO:K09091] 23462 HEY1; hes related family bHLH transcription factor with YRPW motif 1 [KO:K09091] 23493 HEY2; hes related family bHLH transcription factor with YRPW motif 2 [KO:K09091] 2324 FLT4; fms related receptor tyrosine kinase 4 [KO:K05097] [EC:2.7.10.1] 6469 SHH; sonic hedgehog signaling molecule [KO:K11988] 5727 PTCH1; patched 1 [KO:K06225] 6608 SMO; smoothened, frizzled class receptor [KO:K06226] 374654 KIF7; kinesin family member 7 [KO:K18806] 51684 SUFU; SUFU negative regulator of hedgehog signaling [KO:K06229] 2735 GLI1; GLI family zinc finger 1 [KO:K16797] 2736 GLI2; GLI family zinc finger 2 [KO:K16798] 2737 GLI3; GLI family zinc finger 3 [KO:K06230] 650 BMP2; bone morphogenetic protein 2 [KO:K21283] 652 BMP4; bone morphogenetic protein 4 [KO:K04662] 64399 HHIP; hedgehog interacting protein [KO:K06231] 8643 PTCH2; patched 2 [KO:K11101] 367 AR; androgen receptor [KO:K08557] 3320 HSP90AA1; heat shock protein 90 alpha family class A member 1 [KO:K04079] 3326 HSP90AB1; heat shock protein 90 alpha family class B member 1 [KO:K04079] 7184 HSP90B1; heat shock protein 90 beta family member 1 [KO:K09487] 354 KLK3; kallikrein related peptidase 3 [KO:K01351] [EC:3.4.21.77] COMPOUND C00027 Hydrogen peroxide C00039 DNA C00076 Calcium cation C00122 Fumarate C00149 (S)-Malate C00165 Diacylglycerol C00187 Cholesterol C00280 Androstenedione C00410 Progesterone C00416 Phosphatidate C00533 Nitric oxide C00535 Testosterone C00575 3',5'-Cyclic AMP C00584 Prostaglandin E2 C00681 1-Acyl-sn-glycerol 3-phosphate C00704 Superoxide C00735 Cortisol C00762 Cortisone C00777 Retinoate C00951 Estradiol-17beta C01227 Dehydroepiandrosterone C01245 D-myo-Inositol 1,4,5-trisphosphate C01471 Acrolein C03917 Dihydrotestosterone C05981 Phosphatidylinositol-3,4,5-trisphosphate C07653 Flutamide C15493 9-cis-Retinoic acid C16038 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine C16844 Hydroxyl radical C21641 Hydroperoxyl radical C21642 4-Hydroxynonenal REFERENCE AUTHORS Weinberg RA. TITLE The biology of cancer JOURNAL Garland Science, Taylor & Francis Group, LLC (2007) REFERENCE PMID:10647931 AUTHORS Hanahan D, Weinberg RA TITLE The hallmarks of cancer. JOURNAL Cell 100:57-70 (2000) DOI:10.1016/S0092-8674(00)81683-9 REFERENCE PMID:15000146 AUTHORS Grady WM. TITLE Genomic instability and colon cancer. JOURNAL Cancer Metastasis Rev 23:11-27 (2004) DOI:10.1023/A:1025861527711 REFERENCE PMID:16555243 AUTHORS Soreide K, Janssen EA, Soiland H, Korner H, Baak JP. TITLE Microsatellite instability in colorectal cancer. JOURNAL Br J Surg 93:395-406 (2006) DOI:10.1002/bjs.5328 REFERENCE PMID:11078609 AUTHORS Anwar S, Hall C, White J, Deakin M, Farrell W, Elder JB. TITLE Hereditary non-polyposis colorectal cancer: an updated review. JOURNAL Eur J Surg Oncol 26:635-45 (2000) DOI:10.1053/ejso.2000.0974 REFERENCE PMID:16699851 AUTHORS Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. TITLE Colorectal cancer: genetics of development and metastasis. JOURNAL J Gastroenterol 41:185-92 (2006) DOI:10.1007/s00535-006-1801-6 REFERENCE PMID:12621137 AUTHORS Lynch HT, de la Chapelle A. TITLE Hereditary colorectal cancer. JOURNAL N Engl J Med 348:919-32 (2003) DOI:10.1056/NEJMra012242 REFERENCE PMID:12951588 AUTHORS Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. TITLE The significance of unstable chromosomes in colorectal cancer. JOURNAL Nat Rev Cancer 3:695-701 (2003) DOI:10.1038/nrc1165 REFERENCE PMID:10505543 AUTHORS Behrens J. TITLE Cadherins and catenins: role in signal transduction and tumor progression. JOURNAL Cancer Metastasis Rev 18:15-30 (1999) DOI:10.1023/A:1006200102166 REFERENCE PMID:16042571 AUTHORS Behrens J. TITLE The role of the Wnt signalling pathway in colorectal tumorigenesis. JOURNAL Biochem Soc Trans 33:672-5 (2005) DOI:10.1042/BST0330672 REFERENCE PMID:15349822 AUTHORS Behrens J, Lustig B. TITLE The Wnt connection to tumorigenesis. JOURNAL Int J Dev Biol 48:477-87 (2004) DOI:10.1387/ijdb.041815jb REFERENCE PMID:9196022 AUTHORS Polakis P. TITLE The adenomatous polyposis coli (APC) tumor suppressor. JOURNAL Biochim Biophys Acta 1332:F127-47 (1997) DOI:10.1016/S0304-419X(97)00008-5 REFERENCE PMID:12737309 AUTHORS Janssen KP. TITLE Murine models of colorectal cancer: studying the role of oncogenic K-ras. JOURNAL Cell Mol Life Sci 60:495-506 (2003) DOI:10.1007/s000180300041 REFERENCE PMID:11459867 AUTHORS Adjei AA. TITLE Blocking oncogenic Ras signaling for cancer therapy. JOURNAL J Natl Cancer Inst 93:1062-74 (2001) DOI:10.1093/jnci/93.14.1062 REFERENCE PMID:15573119 AUTHORS Arakawa H. TITLE Netrin-1 and its receptors in tumorigenesis. JOURNAL Nat Rev Cancer 4:978-87 (2004) DOI:10.1038/nrc1504 REFERENCE PMID:15310786 AUTHORS Mehlen P, Fearon ER. TITLE Role of the dependence receptor DCC in colorectal cancer pathogenesis. JOURNAL J Clin Oncol 22:3420-8 (2004) DOI:10.1200/JCO.2004.02.019 REFERENCE PMID:11223406 AUTHORS Peltomaki P. TITLE DNA mismatch repair and cancer. JOURNAL Mutat Res 488:77-85 (2001) DOI:10.1016/S1383-5742(00)00058-2 REFERENCE PMID:15711891 AUTHORS Li F, Cao Y, Townsend CM Jr, Ko TC. TITLE TGF-beta signaling in colon cancer cells. JOURNAL World J Surg 29:306-11 (2005) DOI:10.1007/s00268-004-7813-6 REFERENCE PMID:11170304 AUTHORS Roman C, Saha D, Beauchamp R. TITLE TGF-beta and colorectal carcinogenesis. JOURNAL Microsc Res Tech 52:450-7 (2001) DOI:10.1002/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O REFERENCE PMID:16326109 AUTHORS Watson AJ. TITLE An overview of apoptosis and the prevention of colorectal cancer. JOURNAL Crit Rev Oncol Hematol 57:107-21 (2006) DOI:10.1016/j.critrevonc.2005.06.005 REFERENCE PMID:15479695 AUTHORS Watson AJ. TITLE Apoptosis and colorectal cancer. JOURNAL Gut 53:1701-9 (2004) DOI:10.1136/gut.2004.052704 REFERENCE PMID:11477132 AUTHORS Houlston RS. TITLE What we could do now: molecular pathology of colorectal cancer. JOURNAL Mol Pathol 54:206-14 (2001) DOI:10.1136/mp.54.4.206 REFERENCE AUTHORS Von Hoff D, Evans D, Hruban R (ed). TITLE Pancreatic cancer JOURNAL Jones and Bartlett publishers (2005) REFERENCE AUTHORS Niitsu Y, Yokota J (ed). TITLE [Oncogenes and Tumor Suppressor Genes for Medical Oncologist] (In Japanese) JOURNAL Nankodo (1999) REFERENCE PMID:12459728 AUTHORS Bardeesy N, DePinho RA. TITLE Pancreatic cancer biology and genetics. JOURNAL Nat Rev Cancer 2:897-909 (2002) DOI:10.1038/nrc949 REFERENCE PMID:11407945 AUTHORS Bardeesy N, Sharpless NE, DePinho RA, Merlino G. TITLE The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model. JOURNAL Semin Cancer Biol 11:201-18 (2001) DOI:10.1006/scbi.2000.0371 REFERENCE PMID:12946833 AUTHORS Cowgill SM, Muscarella P. TITLE The genetics of pancreatic cancer. JOURNAL Am J Surg 186:279-86 (2003) DOI:10.1016/S0002-9610(03)00226-5 REFERENCE PMID:16702400 AUTHORS Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. TITLE Genetics and biology of pancreatic ductal adenocarcinoma. JOURNAL Genes Dev 20:1218-49 (2006) DOI:10.1101/gad.1415606 REFERENCE PMID:10740269 AUTHORS Shields JM, Pruitt K, McFall A, Shaub A, Der CJ. TITLE Understanding Ras: 'it ain't over 'til it's over'. JOURNAL Trends Cell Biol 10:147-54 (2000) DOI:10.1016/S0962-8924(00)01740-2 REFERENCE PMID:12648469 AUTHORS Holbro T, Civenni G, Hynes NE. TITLE The ErbB receptors and their role in cancer progression. JOURNAL Exp Cell Res 284:99-110 (2003) DOI:10.1016/S0014-4827(02)00099-X REFERENCE PMID:14967450 AUTHORS Marmor MD, Skaria KB, Yarden Y. TITLE Signal transduction and oncogenesis by ErbB/HER receptors. JOURNAL Int J Radiat Oncol Biol Phys 58:903-13 (2004) DOI:10.1016/j.ijrobp.2003.06.002 REFERENCE PMID:14586404 AUTHORS DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW. TITLE Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. JOURNAL Oncogene 22:7781-95 (2003) DOI:10.1038/sj.onc.1206966 REFERENCE PMID:12545153 AUTHORS Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K. TITLE Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. JOURNAL Oncogene 22:319-29 (2003) DOI:10.1038/sj.onc.1206122 REFERENCE PMID:14580692 AUTHORS Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M. TITLE Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. JOURNAL Cancer Lett 201:107-16 (2003) DOI:10.1016/S0304-3835(03)00482-8 REFERENCE PMID:12079267 AUTHORS Schmid RM. TITLE Genetic basis of pancreatic cancer. JOURNAL Best Pract Res Clin Gastroenterol 16:421-33 (2002) DOI:10.1053/bega.2002.0316 REFERENCE PMID:15774796 AUTHORS Elliott RL, Blobe GC. TITLE Role of transforming growth factor Beta in human cancer. JOURNAL J Clin Oncol 23:2078-93 (2005) DOI:10.1200/JCO.2005.02.047 REFERENCE PMID:15823750 AUTHORS Rudkin TM, Foulkes WD. TITLE BRCA2: breaks, mistakes and failed separations. JOURNAL Trends Mol Med 11:145-8 (2005) DOI:10.1016/j.molmed.2005.02.003 REFERENCE PMID:11707511 AUTHORS Venkitaraman AR. TITLE Functions of BRCA1 and BRCA2 in the biological response to DNA damage. JOURNAL J Cell Sci 114:3591-8 (2001) REFERENCE PMID:15639402 AUTHORS Soni D, King JA, Kaye AH, Hovens CM. TITLE Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. JOURNAL J Clin Neurosci 12:1-5 (2005) DOI:10.1016/j.jocn.2004.04.001 REFERENCE PMID:12154354 AUTHORS Zhu Y, Parada LF. TITLE The molecular and genetic basis of neurological tumours. JOURNAL Nat Rev Cancer 2:616-26 (2002) DOI:10.1038/nrc866 REFERENCE PMID:11253051 AUTHORS Holland EC. TITLE Gliomagenesis: genetic alterations and mouse models. JOURNAL Nat Rev Genet 2:120-9 (2001) DOI:10.1038/35052535 REFERENCE PMID:16700615 AUTHORS Bansal K, Liang ML, Rutka JT. TITLE Molecular biology of human gliomas. JOURNAL Technol Cancer Res Treat 5:185-94 (2006) DOI:10.1177/153303460600500302 REFERENCE AUTHORS Tabuchi K (ed). TITLE [Gliomas: Research and therapy] (In Japanese) JOURNAL Springer-Verlag Tokyo (2006) REFERENCE PMID:12762887 AUTHORS Kapoor GS, O'Rourke DM. TITLE Mitogenic signaling cascades in glial tumors. JOURNAL Neurosurgery 52:1425-34; discussion 1434-5 (2003) DOI:10.1227/01.NEU.0000065135.28143.39 REFERENCE PMID:16095998 AUTHORS Hulleman E, Helin K. TITLE Molecular mechanisms in gliomagenesis. JOURNAL Adv Cancer Res 94:1-27 (2005) DOI:10.1016/S0065-230X(05)94001-3 REFERENCE PMID:11057895 AUTHORS Schlessinger J. TITLE Cell signaling by receptor tyrosine kinases. JOURNAL Cell 103:211-25 (2000) DOI:10.1016/S0092-8674(00)00114-8 REFERENCE PMID:9643506 AUTHORS Ng HK, Lam PY. TITLE The molecular genetics of central nervous system tumors. JOURNAL Pathology 30:196-202 (1998) DOI:10.1080/00313029800169236 REFERENCE PMID:12084351 AUTHORS Knobbe CB, Merlo A, Reifenberger G. TITLE Pten signaling in gliomas. JOURNAL Neuro-oncol 4:196-211 (2002) DOI:10.1093/neuonc/4.3.196 REFERENCE PMID:16557281 AUTHORS Kondo T, Ezzat S, Asa SL. TITLE Pathogenetic mechanisms in thyroid follicular-cell neoplasia. JOURNAL Nat Rev Cancer 6:292-306 (2006) DOI:10.1038/nrc1836 REFERENCE PMID:16551846 AUTHORS Chiloeches A, Marais R. TITLE Is BRAF the Achilles' Heel of thyroid cancer? JOURNAL Clin Cancer Res 12:1661-4 (2006) DOI:10.1158/1078-0432.CCR-06-0051 REFERENCE PMID:16946003 AUTHORS Reddi HV, McIver B, Grebe SK, Eberhardt NL TITLE The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. JOURNAL Endocrinology 148:932-5 (2007) DOI:10.1210/en.2006-0926 REFERENCE PMID:17062879 AUTHORS Santoro M, Melillo RM, Fusco A. TITLE RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. JOURNAL Eur J Endocrinol 155:645-653 (2006) DOI:10.1530/eje.1.02289 REFERENCE PMID:16242838 AUTHORS Pierotti MA, Greco A. TITLE Oncogenic rearrangements of the NTRK1/NGF receptor. JOURNAL Cancer Lett 232:90-8 (2006) DOI:10.1016/j.canlet.2005.07.043 REFERENCE PMID:16189702 AUTHORS Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P. TITLE Molecular pathology of well-differentiated thyroid carcinomas. JOURNAL Virchows Arch 447:787-93 (2005) DOI:10.1007/s00428-005-0065-5 REFERENCE PMID:11165748 AUTHORS Gimm O. TITLE Thyroid cancer. JOURNAL Cancer Lett 163:143-56 (2001) DOI:10.1016/S0304-3835(00)00697-2 REFERENCE PMID:12094241 AUTHORS Williams D. TITLE Cancer after nuclear fallout: lessons from the Chernobyl accident. JOURNAL Nat Rev Cancer 2:543-9 (2002) DOI:10.1038/nrc845 REFERENCE PMID:16236521 AUTHORS Steffen B, Muller-Tidow C, Schwable J, Berdel WE, Serve H. TITLE The molecular pathogenesis of acute myeloid leukemia. JOURNAL Crit Rev Oncol Hematol 56:195-221 (2005) DOI:10.1016/j.critrevonc.2004.10.012 REFERENCE PMID:12563308 AUTHORS Tenen DG. TITLE Disruption of differentiation in human cancer: AML shows the way. JOURNAL Nat Rev Cancer 3:89-101 (2003) DOI:10.1038/nrc989 REFERENCE PMID:16146838 AUTHORS Choudhary C, Muller-Tidow C, Berdel WE, Serve H. TITLE Signal transduction of oncogenic Flt3. JOURNAL Int J Hematol 82:93-9 (2005) DOI:10.1532/IJH97.05090 REFERENCE PMID:12951584 AUTHORS Stirewalt DL, Radich JP. TITLE The role of FLT3 in haematopoietic malignancies. JOURNAL Nat Rev Cancer 3:650-65 (2003) DOI:10.1038/nrc1169 REFERENCE PMID:16642045 AUTHORS Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L. TITLE Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. JOURNAL Leukemia 20:911-28 (2006) DOI:10.1038/sj.leu.2404245 REFERENCE PMID:15625120 AUTHORS Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R. TITLE Normal and oncogenic forms of the receptor tyrosine kinase kit. JOURNAL Stem Cells 23:16-43 (2005) DOI:10.1634/stemcells.2004-0117 REFERENCE PMID:11721960 AUTHORS Lorsbach RB, Downing JR. TITLE The role of the AML1 transcription factor in leukemogenesis. JOURNAL Int J Hematol 74:258-65 (2001) DOI:10.1007/BF02982058 REFERENCE PMID:12468433 AUTHORS Mizuki M, Schwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H. TITLE Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. JOURNAL Blood 101:3164-73 (2003) DOI:10.1182/blood-2002-06-1677 REFERENCE PMID:17554387 AUTHORS Mikesch JH, Steffen B, Berdel WE, Serve H, Muller-Tidow C. TITLE The emerging role of Wnt signaling in the pathogenesis of acute myeloid leukemia. JOURNAL Leukemia 21:1638-47 (2007) DOI:10.1038/sj.leu.2404732 REFERENCE PMID:16352814 AUTHORS Mueller BU, Pabst T, Fos J, Petkovic V, Fey MF, Asou N, Buergi U, Tenen DG. TITLE ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression. JOURNAL Blood 107:3330-8 (2006) DOI:10.1182/blood-2005-07-3068 REFERENCE PMID:15719031 AUTHORS Ren R. TITLE Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. JOURNAL Nat Rev Cancer 5:172-83 (2005) DOI:10.1038/nrc1567 REFERENCE PMID:11071626 AUTHORS Deininger MW, Goldman JM, Melo JV. TITLE The molecular biology of chronic myeloid leukemia. JOURNAL Blood 96:3343-56 (2000) REFERENCE PMID:14982876 AUTHORS Calabretta B, Perrotti D. TITLE The biology of CML blast crisis. JOURNAL Blood 103:4010-22 (2004) DOI:10.1182/blood-2003-12-4111 REFERENCE PMID:10403855 AUTHORS Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. TITLE The biology of chronic myeloid leukemia. JOURNAL N Engl J Med 341:164-72 (1999) DOI:10.1056/NEJM199907153410306 REFERENCE PMID:15156182 AUTHORS Mitani K. TITLE Molecular mechanisms of leukemogenesis by AML1/EVI-1. JOURNAL Oncogene 23:4263-9 (2004) DOI:10.1038/sj.onc.1207777 REFERENCE PMID:16484590 AUTHORS Dong M, Blobe GC. TITLE Role of transforming growth factor-beta in hematologic malignancies. JOURNAL Blood 107:4589-96 (2006) DOI:10.1182/blood-2005-10-4169 REFERENCE PMID:9834202 AUTHORS Kurokawa M, Mitani K, Imai Y, Ogawa S, Yazaki Y, Hirai H. TITLE The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells. JOURNAL Blood 92:4003-12 (1998) REFERENCE PMID:12801837 AUTHORS Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA. TITLE p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. JOURNAL Haematologica 88:622-30 (2003) REFERENCE PMID:11160144 AUTHORS Baldwin AS. TITLE Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. JOURNAL J Clin Invest 107:241-6 (2001) DOI:10.1172/JCI11991 REFERENCE PMID:12244301 AUTHORS Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. TITLE PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. JOURNAL Nat Med 8:1145-52 (2002) DOI:10.1038/nm759 REFERENCE PMID:15948971 AUTHORS Tilli CM, Van Steensel MA, Krekels GA, Neumann HA, Ramaekers FC. TITLE Molecular aetiology and pathogenesis of basal cell carcinoma. JOURNAL Br J Dermatol 152:1108-24 (2005) DOI:10.1111/j.1365-2133.2005.06587.x REFERENCE PMID:12588368 AUTHORS Saldanha G, Fletcher A, Slater DN. TITLE Basal cell carcinoma: a dermatopathological and molecular biological update. JOURNAL Br J Dermatol 148:195-202 (2003) DOI:10.1046/j.1365-2133.2003.05151.x REFERENCE PMID:15978322 AUTHORS Daya-Grosjean L, Couve-Privat S. TITLE Sonic hedgehog signaling in basal cell carcinomas. JOURNAL Cancer Lett 225:181-92 (2005) DOI:10.1016/j.canlet.2004.10.003 REFERENCE PMID:15468170 AUTHORS Tsai KY, Tsao H. TITLE The genetics of skin cancer. JOURNAL Am J Med Genet C Semin Med Genet 131C:82-92 (2004) DOI:10.1002/ajmg.c.30037 REFERENCE PMID:16881963 AUTHORS Athar M, Tang X, Lee JL, Kopelovich L, Kim AL. TITLE Hedgehog signalling in skin development and cancer. JOURNAL Exp Dermatol 15:667-77 (2006) DOI:10.1111/j.1600-0625.2006.00473.x REFERENCE PMID:16306523 AUTHORS Rubin AI, Chen EH, Ratner D. TITLE Basal-cell carcinoma. JOURNAL N Engl J Med 353:2262-9 (2005) DOI:10.1056/NEJMra044151 REFERENCE PMID:11276000 AUTHORS Saldanha G. TITLE The Hedgehog signalling pathway and cancer. JOURNAL J Pathol 193:427-32 (2001) DOI:10.1002/1096-9896(2000)9999:9999<::AID-PATH815>3.0.CO;2-N REFERENCE PMID:15270885 AUTHORS Saldanha G, Ghura V, Potter L, Fletcher A. TITLE Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. JOURNAL Br J Dermatol 151:157-64 (2004) DOI:10.1111/j.1365-2133.2004.06048.x REFERENCE PMID:14737121 AUTHORS Pasca di Magliano M, Hebrok M. TITLE Hedgehog signalling in cancer formation and maintenance. JOURNAL Nat Rev Cancer 3:903-11 (2003) DOI:10.1038/nrc1229 REFERENCE PMID:15656799 AUTHORS Reifenberger J, Wolter M, Knobbe CB, Kohler B, Schonicke A, Scharwachter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G. TITLE Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. JOURNAL Br J Dermatol 152:43-51 (2005) DOI:10.1111/j.1365-2133.2005.06353.x REFERENCE PMID:14556242 AUTHORS Cohen MM Jr. TITLE The hedgehog signaling network. JOURNAL Am J Med Genet A 123:5-28 (2003) DOI:10.1002/ajmg.a.20495 REFERENCE PMID:11736900 AUTHORS Yamazaki F, Aragane Y, Kawada A, Tezuka T. TITLE Immunohistochemical detection for nuclear beta-catenin in sporadic basal cell carcinoma. JOURNAL Br J Dermatol 145:771-7 (2001) DOI:10.1046/j.1365-2133.2001.04468.x REFERENCE PMID:16054233 AUTHORS Erb P, Ji J, Wernli M, Kump E, Glaser A, Buchner SA. TITLE Role of apoptosis in basal cell and squamous cell carcinoma formation. JOURNAL Immunol Lett 100:68-72 (2005) DOI:10.1016/j.imlet.2005.06.008 REFERENCE PMID:11130178 AUTHORS Toftgard R. TITLE Hedgehog signalling in cancer. JOURNAL Cell Mol Life Sci 57:1720-31 (2000) DOI:10.1007/PL00000654 REFERENCE PMID:16822996 AUTHORS Miller AJ, Mihm MC Jr. TITLE Melanoma. JOURNAL N Engl J Med 355:51-65 (2006) DOI:10.1056/NEJMra052166 REFERENCE PMID:12894244 AUTHORS Chin L. TITLE The genetics of malignant melanoma: lessons from mouse and man. JOURNAL Nat Rev Cancer 3:559-70 (2003) DOI:10.1038/nrc1145 REFERENCE PMID:16750612 AUTHORS Takata M, Saida T. TITLE Genetic alterations in melanocytic tumors. JOURNAL J Dermatol Sci 43:1-10 (2006) DOI:10.1016/j.jdermsci.2006.05.002 REFERENCE PMID:15841168 AUTHORS Chudnovsky Y, Khavari PA, Adams AE. TITLE Melanoma genetics and the development of rational therapeutics. JOURNAL J Clin Invest 115:813-24 (2005) DOI:10.1172/JCI24808 REFERENCE PMID:16001050 AUTHORS Merlino G. TITLE Cancer biology: the weakest link? JOURNAL Nature 436:33-5 (2005) DOI:10.1038/436033a REFERENCE PMID:16001072 AUTHORS Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR. TITLE Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. JOURNAL Nature 436:117-22 (2005) DOI:10.1038/nature03664 REFERENCE PMID:16899407 AUTHORS Levy C, Khaled M, Fisher DE. TITLE MITF: master regulator of melanocyte development and melanoma oncogene. JOURNAL Trends Mol Med 12:406-14 (2006) DOI:10.1016/j.molmed.2006.07.008 REFERENCE PMID:15009714 AUTHORS Tsao H, Goel V, Wu H, Yang G, Haluska FG. TITLE Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. JOURNAL J Invest Dermatol 122:337-41 (2004) DOI:10.1046/j.0022-202X.2004.22243.x REFERENCE PMID:11224709 AUTHORS Gruss C, Herlyn M. TITLE Role of cadherins and matrixins in melanoma. JOURNAL Curr Opin Oncol 13:117-23 (2001) DOI:10.1097/00001622-200103000-00006 REFERENCE PMID:15721476 AUTHORS Thompson JF, Scolyer RA, Kefford RF. TITLE Cutaneous melanoma. JOURNAL Lancet 365:687-701 (2005) DOI:10.1016/S0140-6736(05)17951-3 REFERENCE PMID:14695152 AUTHORS Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. TITLE NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. JOURNAL Clin Cancer Res 9:6483-8 (2003) REFERENCE PMID:15557758 AUTHORS Hussein MR. TITLE The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship? JOURNAL Tumour Biol 25:200-7 (2004) DOI:10.1159/000081103 REFERENCE PMID:10843728 AUTHORS Lazar-Molnar E, Hegyesi H, Toth S, Falus A. TITLE Autocrine and paracrine regulation by cytokines and growth factors in melanoma. JOURNAL Cytokine 12:547-54 (2000) DOI:10.1006/cyto.1999.0614 REFERENCE PMID:16339096 AUTHORS Cohen HT, McGovern FJ. TITLE Renal-cell carcinoma. JOURNAL N Engl J Med 353:2477-90 (2005) DOI:10.1056/NEJMra043172 REFERENCE PMID:15122209 AUTHORS Pavlovich CP, Schmidt LS. TITLE Searching for the hereditary causes of renal-cell carcinoma. JOURNAL Nat Rev Cancer 4:381-93 (2004) DOI:10.1038/nrc1364 REFERENCE PMID:14634372 AUTHORS Linehan WM, Walther MM, Zbar B. TITLE The genetic basis of cancer of the kidney. JOURNAL J Urol 170:2163-72 (2003) DOI:10.1097/01.ju.0000096060.92397.ed REFERENCE PMID:14685170 AUTHORS Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. TITLE Met, metastasis, motility and more. JOURNAL Nat Rev Mol Cell Biol 4:915-25 (2003) DOI:10.1038/nrm1261 REFERENCE PMID:15611513 AUTHORS Kim WY, Kaelin WG. TITLE Role of VHL gene mutation in human cancer. JOURNAL J Clin Oncol 22:4991-5004 (2004) DOI:10.1200/JCO.2004.05.061 REFERENCE PMID:17211469 AUTHORS Sudarshan S, Linehan WM, Neckers L. TITLE HIF and fumarate hydratase in renal cancer. JOURNAL Br J Cancer 96:403-7 (2007) DOI:10.1038/sj.bjc.6603547 REFERENCE PMID:17287871 AUTHORS Sudarshan S, Pinto PA, Neckers L, Linehan WM. TITLE Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer. JOURNAL Nat Clin Pract Urol 4:104-10 (2007) DOI:10.1038/ncpuro0711 REFERENCE PMID:12351585 AUTHORS Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG. TITLE Understanding familial and non-familial renal cell cancer. JOURNAL Hum Mol Genet 11:2489-98 (2002) DOI:10.1093/hmg/11.20.2489 REFERENCE PMID:17158541 AUTHORS Mitra AP, Datar RH, Cote RJ. TITLE Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. JOURNAL J Clin Oncol 24:5552-64 (2006) DOI:10.1200/JCO.2006.08.2073 REFERENCE PMID:16474624 AUTHORS Wolff EM, Liang G, Jones PA. TITLE Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer. JOURNAL Nat Clin Pract Urol 2:502-10 (2005) DOI:10.1038/ncpuro0318 REFERENCE PMID:16110317 AUTHORS Wu XR. TITLE Urothelial tumorigenesis: a tale of divergent pathways. JOURNAL Nat Rev Cancer 5:713-25 (2005) DOI:10.1038/nrc1697 REFERENCE PMID:11103787 AUTHORS Brown NS, Jones A, Fujiyama C, Harris AL, Bicknell R. TITLE Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. JOURNAL Cancer Res 60:6298-302 (2000) REFERENCE PMID:12850530 AUTHORS Bellmunt J, Hussain M, Dinney CP. TITLE Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. JOURNAL Crit Rev Oncol Hematol 46 Suppl:S85-104 (2003) DOI:10.1016/S1040-8428(03)00067-2 REFERENCE PMID:17149381 AUTHORS Sugano K, Kakizoe T. TITLE Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging. JOURNAL Nat Clin Pract Urol 3:642-52 (2006) DOI:10.1038/ncpuro0649 REFERENCE PMID:15746962 AUTHORS Dunn KL, Espino PS, Drobic B, He S, Davie JR. TITLE The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. JOURNAL Biochem Cell Biol 83:1-14 (2005) DOI:10.1139/o04-121 REFERENCE PMID:15551095 AUTHORS Williams SG, Stein JP. TITLE Molecular pathways in bladder cancer. JOURNAL Urol Res 32:373-85 (2004) DOI:10.1007/s00240-003-0345-y REFERENCE PMID:12878745 AUTHORS Nelson WG, De Marzo AM, Isaacs WB. TITLE Prostate cancer. JOURNAL N Engl J Med 349:366-81 (2003) DOI:10.1056/NEJMra021562 REFERENCE PMID:15724144 AUTHORS Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC. TITLE The emerging role of the PI3-K-Akt pathway in prostate cancer progression. JOURNAL Prostate Cancer Prostatic Dis 8:108-18 (2005) DOI:10.1038/sj.pcan.4500776 REFERENCE PMID:16551847 AUTHORS Pienta KJ, Bradley D. TITLE Mechanisms underlying the development of androgen-independent prostate cancer. JOURNAL Clin Cancer Res 12:1665-71 (2006) DOI:10.1158/1078-0432.CCR-06-0067 REFERENCE PMID:11900250 AUTHORS Feldman BJ, Feldman D. TITLE The development of androgen-independent prostate cancer. JOURNAL Nat Rev Cancer 1:34-45 (2001) DOI:10.1038/35094009 REFERENCE PMID:15082523 AUTHORS Heinlein CA, Chang C. TITLE Androgen receptor in prostate cancer. JOURNAL Endocr Rev 25:276-308 (2004) DOI:10.1210/er.2002-0032 REFERENCE PMID:9422516 AUTHORS Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. TITLE Androgen receptor gene and hormonal therapy failure of prostate cancer. JOURNAL Am J Pathol 152:1-9 (1998) REFERENCE PMID:10835690 AUTHORS Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. TITLE Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. JOURNAL Nat Med 6:703-6 (2000) DOI:10.1038/76287 REFERENCE PMID:10453277 AUTHORS Macri E, Loda M. TITLE Role of p27 in prostate carcinogenesis. JOURNAL Cancer Metastasis Rev 17:337-44 (1998) DOI:10.1023/A:1006133620914 REFERENCE PMID:11750244 AUTHORS Steers WD. TITLE 5alpha-reductase activity in the prostate. JOURNAL Urology 58:17-24; discussion 24 (2001) DOI:10.1016/S0090-4295(01)01299-7 REFERENCE PMID:8069858 AUTHORS Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF. TITLE Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis. JOURNAL Cancer Res 54:4920-6 (1994) REFERENCE PMID:11527574 AUTHORS Grimes CA, Jope RS. TITLE The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. JOURNAL Prog Neurobiol 65:391-426 (2001) DOI:10.1016/S0301-0082(01)00011-9 REFERENCE PMID:15947972 AUTHORS Ryan AJ, Susil B, Jobling TW, Oehler MK. TITLE Endometrial cancer. JOURNAL Cell Tissue Res 322:53-61 (2005) DOI:10.1007/s00441-005-1109-5 REFERENCE PMID:14747944 AUTHORS Lax SF. TITLE Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. JOURNAL Virchows Arch 444:213-23 (2004) DOI:10.1007/s00428-003-0947-3 REFERENCE PMID:16508724 AUTHORS Shiozawa T, Konishi I. TITLE Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. JOURNAL Int J Clin Oncol 11:13-21 (2006) DOI:10.1007/s10147-005-0546-1 REFERENCE PMID:17028294 AUTHORS Hecht JL, Mutter GL. TITLE Molecular and pathologic aspects of endometrial carcinogenesis. JOURNAL J Clin Oncol 24:4783-91 (2006) DOI:10.1200/JCO.2006.06.7173 REFERENCE PMID:11431710 AUTHORS Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Munoz J, Arguelles R, Machin P, Prat J. TITLE Molecular pathology of endometrial hyperplasia and carcinoma. JOURNAL Hum Pathol 32:569-77 (2001) DOI:10.1053/hupa.2001.25929 REFERENCE PMID:15284264 AUTHORS Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH. TITLE Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. JOURNAL J Clin Oncol 22:3126-32 (2004) DOI:10.1200/JCO.2004.11.154 REFERENCE PMID:7585656 AUTHORS Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF. TITLE Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. JOURNAL Cancer Res 55:5693-8 (1995) REFERENCE PMID:16248975 AUTHORS Kim D, Chung J. TITLE Akt: versatile mediator of cell survival and beyond. JOURNAL J Biochem Mol Biol 35:106-15 (2002) DOI:10.5483/bmbrep.2002.35.1.106 REFERENCE PMID:12711111 AUTHORS Sanchez-Cespedes M. TITLE Dissecting the genetic alterations involved in lung carcinogenesis. JOURNAL Lung Cancer 40:111-21 (2003) DOI:10.1016/S0169-5002(03)00033-3 REFERENCE PMID:11720739 AUTHORS Kaye FJ. TITLE Molecular biology of lung cancer. JOURNAL Lung Cancer 34 Suppl 2:S35-41 (2001) DOI:10.1016/S0169-5002(01)00342-7 REFERENCE PMID:12616528 AUTHORS Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. TITLE Apoptosis and lung cancer: a review. JOURNAL J Cell Biochem 88:885-98 (2003) DOI:10.1002/jcb.10440 REFERENCE PMID:11807782 AUTHORS Sartorius UA, Krammer PH. TITLE Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. JOURNAL Int J Cancer 97:584-92 (2002) DOI:10.1002/ijc.10096 REFERENCE PMID:16064138 AUTHORS Adhikary S, Eilers M. TITLE Transcriptional regulation and transformation by Myc proteins. JOURNAL Nat Rev Mol Cell Biol 6:635-45 (2005) DOI:10.1038/nrm1703 REFERENCE PMID:11463388 AUTHORS Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW, Reed SI. TITLE A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. JOURNAL Mol Cell 7:639-50 (2001) DOI:10.1016/S1097-2765(01)00210-6 REFERENCE PMID:15109562 AUTHORS Buttery RC, Rintoul RC, Sethi T. TITLE Small cell lung cancer: the importance of the extracellular matrix. JOURNAL Int J Biochem Cell Biol 36:1154-60 (2004) DOI:10.1016/S1357-2725(03)00261-9 REFERENCE PMID:11559746 AUTHORS Yamada KM, Araki M. TITLE Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. JOURNAL J Cell Sci 114:2375-82 (2001) REFERENCE PMID:11905738 AUTHORS Rintoul RC, Sethi T. TITLE The role of extracellular matrix in small-cell lung cancer. JOURNAL Lancet Oncol 2:437-42 (2001) DOI:10.1016/S1470-2045(00)00421-6 REFERENCE PMID:12243753 AUTHORS Ekedahl J, Joseph B, Grigoriev MY, Muller M, Magnusson C, Lewensohn R, Zhivotovsky B. TITLE Expression of inhibitor of apoptosis proteins in small- and non-small-cell lung carcinoma cells. JOURNAL Exp Cell Res 279:277-90 (2002) DOI:10.1006/excr.2002.5608 REFERENCE PMID:12379883 AUTHORS Osada H, Takahashi T. TITLE Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. JOURNAL Oncogene 21:7421-34 (2002) DOI:10.1038/sj.onc.1205802 REFERENCE PMID:12741677 AUTHORS Yokota J, Nishioka M, Tani M, Kohno T. TITLE Genetic alterations responsible for metastatic phenotypes of lung cancer cells. JOURNAL Clin Exp Metastasis 20:189-93 (2003) DOI:10.1023/a:1022978932215 REFERENCE PMID:16870043 AUTHORS Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS. TITLE K-ras mutations in non-small-cell lung carcinoma: a review. JOURNAL Clin Lung Cancer 8:30-8 (2006) DOI:10.3816/CLC.2006.n.030 REFERENCE PMID:15948711 AUTHORS Pfeifer GP, Dammann R. TITLE Methylation of the tumor suppressor gene RASSF1A in human tumors. JOURNAL Biochemistry (Mosc) 70:576-83 (2005) DOI:10.1007/s10541-005-0151-y REFERENCE PMID:11902573 AUTHORS Altucci L, Gronemeyer H. TITLE The promise of retinoids to fight against cancer. JOURNAL Nat Rev Cancer 1:181-93 (2001) DOI:10.1038/35106036 REFERENCE PMID:10944551 AUTHORS Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF. TITLE Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. JOURNAL J Natl Cancer Inst 92:1303-7 (2000) DOI:10.1093/jnci/92.16.1303 REFERENCE PMID:12867060 AUTHORS Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. TITLE Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. JOURNAL Lung Cancer 41 Suppl 1:S29-42 (2003) DOI:10.1016/S0169-5002(03)00137-5 REFERENCE PMID:16112428 AUTHORS Panani AD, Roussos C. TITLE Cytogenetic and molecular aspects of lung cancer. JOURNAL Cancer Lett 239:1-9 (2006) DOI:10.1016/j.canlet.2005.06.030 REFERENCE PMID:12407699 AUTHORS Mitsuuchi Y, Testa JR. TITLE Cytogenetics and molecular genetics of lung cancer. JOURNAL Am J Med Genet 115:183-8 (2002) DOI:10.1002/ajmg.10692 REFERENCE PMID:15942304 AUTHORS Breuer RH, Postmus PE, Smit EF. TITLE Molecular pathology of non-small-cell lung cancer. JOURNAL Respiration 72:313-30 (2005) DOI:10.1159/000085376 REFERENCE PMID:11895903 AUTHORS Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE. TITLE Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. JOURNAL Clin Cancer Res 8:734-44 (2002) REFERENCE PMID:16189154 AUTHORS Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K. TITLE Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. JOURNAL J Clin Pathol 58:1076-80 (2005) DOI:10.1136/jcp.2004.025585 REFERENCE PMID:21193867 AUTHORS Lappano R, Maggiolini M TITLE G protein-coupled receptors: novel targets for drug discovery in cancer. JOURNAL Nat Rev Drug Discov 10:47-60 (2011) DOI:10.1038/nrd3320 REFERENCE PMID:24508914 AUTHORS O'Hayre M, Degese MS, Gutkind JS TITLE Novel insights into G protein and G protein-coupled receptor signaling in cancer. JOURNAL Curr Opin Cell Biol 27:126-35 (2014) DOI:10.1016/j.ceb.2014.01.005 REFERENCE PMID:17251915 AUTHORS Dorsam RT, Gutkind JS TITLE G-protein-coupled receptors and cancer. JOURNAL Nat Rev Cancer 7:79-94 (2007) DOI:10.1038/nrc2069 REL_PATHWAY hsa03320 PPAR signaling pathway hsa04010 MAPK signaling pathway hsa04020 Calcium signaling pathway hsa04024 cAMP signaling pathway hsa04060 Cytokine-cytokine receptor interaction hsa04066 HIF-1 signaling pathway hsa04110 Cell cycle hsa04115 p53 signaling pathway hsa04150 mTOR signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04210 Apoptosis hsa04310 Wnt signaling pathway hsa04330 Notch signaling pathway hsa04340 Hedgehog signaling pathway hsa04350 TGF-beta signaling pathway hsa04370 VEGF signaling pathway hsa04510 Focal adhesion hsa04512 ECM-receptor interaction hsa04520 Adherens junction hsa04630 JAK-STAT signaling pathway hsa04915 Estrogen signaling pathway KO_PATHWAY ko05200 ///